• TRIAL DATA

    Extended Follow-Up Shows Durable Responses with Dual Immunotherapy in MSS Metastatic Colorectal Cancer Without Liver Metastases

    Phase 1b trial of botensilimab (Fc-enhanced anti-CTLA-4) plus balstilimab (anti-PD-1) in patients with microsatellite-stable metastatic colorectal cancer and no active liver metastases reports extended follow-up data on objective response rate, duration of response, and survival outcomes. (Clinical Cancer Research)